Which has stronger earnings & valuation, JANX or TLX?

Telix Pharmaceuticals has higher revenue and earnings than Janux Therapeutics. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Janux Therapeutics $10M 82.69 -$113.62M -$1.84 N/A Telix Pharmaceuticals $803.79M 4.04 -$7.12M N/A N/A

Is JANX or TLX more profitable?

Telix Pharmaceuticals' return on equity of 0.00% beat Janux Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Janux Therapeutics N/A -12.93% -12.23% Telix Pharmaceuticals N/A N/A N/A

Does the media favor JANX or TLX?

In the previous week, Janux Therapeutics had 1 more articles in the media than Telix Pharmaceuticals. MarketBeat recorded 3 mentions for Janux Therapeutics and 2 mentions for Telix Pharmaceuticals. Telix Pharmaceuticals' average media sentiment score of 1.50 beat Janux Therapeutics' score of 1.25 indicating that Telix Pharmaceuticals is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Janux Therapeutics 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Telix Pharmaceuticals 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive

Is DNLI or JANX more profitable?

Janux Therapeutics' return on equity of -12.93% beat Denali Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Denali Therapeutics N/A -52.20% -43.86% Janux Therapeutics N/A -12.93% -12.23%

Does the media prefer BEAM or JANX?

In the previous week, Beam Therapeutics had 2 more articles in the media than Janux Therapeutics. MarketBeat recorded 5 mentions for Beam Therapeutics and 3 mentions for Janux Therapeutics. Beam Therapeutics' average media sentiment score of 1.30 beat Janux Therapeutics' score of 1.25 indicating that Beam Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Beam Therapeutics 3 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Janux Therapeutics 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media favor JANX or TNGX?

In the previous week, Tango Therapeutics had 20 more articles in the media than Janux Therapeutics. MarketBeat recorded 23 mentions for Tango Therapeutics and 3 mentions for Janux Therapeutics. Janux Therapeutics' average media sentiment score of 1.25 beat Tango Therapeutics' score of 0.10 indicating that Janux Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Janux Therapeutics 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Tango Therapeutics 3 Very Positive mention(s) 1 Positive mention(s) 5 Neutral mention(s) 2 Negative mention(s) 6 Very Negative mention(s) Neutral

Does the media refer more to RCUS or JANX?

In the previous week, Arcus Biosciences had 5 more articles in the media than Janux Therapeutics. MarketBeat recorded 8 mentions for Arcus Biosciences and 3 mentions for Janux Therapeutics. Janux Therapeutics' average media sentiment score of 1.25 beat Arcus Biosciences' score of 0.75 indicating that Janux Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Arcus Biosciences 3 Very Positive mention(s) 1 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Janux Therapeutics 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Janux Therapeutics (JANX) Competitors

$13.56 0.00 (0.00%)

Closing price 06/12/2026 04:00 PM Eastern

Extended Trading

$13.57 +0.01 (+0.10%)

As of 06/12/2026 06:04 PM Eastern

Compare

JANX vs. TLX, DNLI, BEAM, TNGX, and RCUS

Should you buy Janux Therapeutics stock or one of its competitors? MarketBeat compares Janux Therapeutics with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Janux Therapeutics include Telix Pharmaceuticals (TLX), Denali Therapeutics (DNLI), Beam Therapeutics (BEAM), Tango Therapeutics (TNGX), and Arcus Biosciences (RCUS). These companies are all part of the "pharmaceutical products" industry.

How does Janux Therapeutics compare to Telix Pharmaceuticals?

Janux Therapeutics (NASDAQ:JANX) and Telix Pharmaceuticals (NASDAQ:TLX) are both medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their media sentiment, institutional ownership, profitability, dividends, earnings, analyst recommendations, valuation and risk.

Janux Therapeutics has a beta of 2.53, suggesting that its share price is 153% more volatile than the broader market. Comparatively, Telix Pharmaceuticals has a beta of -0.1, suggesting that its share price is 110% less volatile than the broader market.

In the previous week, Janux Therapeutics had 1 more articles in the media than Telix Pharmaceuticals. MarketBeat recorded 3 mentions for Janux Therapeutics and 2 mentions for Telix Pharmaceuticals. Telix Pharmaceuticals' average media sentiment score of 1.50 beat Janux Therapeutics' score of 1.25 indicating that Telix Pharmaceuticals is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Janux Therapeutics	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Telix Pharmaceuticals	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive

Janux Therapeutics presently has a consensus price target of $45.85, indicating a potential upside of 238.10%. Telix Pharmaceuticals has a consensus price target of $21.13, indicating a potential upside of 120.97%. Given Janux Therapeutics' higher possible upside, equities research analysts clearly believe Janux Therapeutics is more favorable than Telix Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Janux Therapeutics	2 Sell rating(s)	3 Hold rating(s)	9 Buy rating(s)	1 Strong Buy rating(s)	2.60
Telix Pharmaceuticals	1 Sell rating(s)	1 Hold rating(s)	6 Buy rating(s)	1 Strong Buy rating(s)	2.78

75.4% of Janux Therapeutics shares are owned by institutional investors. 7.9% of Janux Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Telix Pharmaceuticals' return on equity of 0.00% beat Janux Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Janux Therapeutics	N/A	-12.93%	-12.23%
Telix Pharmaceuticals	N/A	N/A	N/A

Telix Pharmaceuticals has higher revenue and earnings than Janux Therapeutics.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Janux Therapeutics	$10M	82.69	-$113.62M	-$1.84	N/A
Telix Pharmaceuticals	$803.79M	4.04	-$7.12M	N/A	N/A

Summary

Janux Therapeutics beats Telix Pharmaceuticals on 7 of the 13 factors compared between the two stocks.

How does Janux Therapeutics compare to Denali Therapeutics?

Denali Therapeutics (NASDAQ:DNLI) and Janux Therapeutics (NASDAQ:JANX) are both medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their risk, media sentiment, dividends, profitability, earnings, analyst recommendations, valuation and institutional ownership.

Janux Therapeutics' return on equity of -12.93% beat Denali Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Denali Therapeutics	N/A	-52.20%	-43.86%
Janux Therapeutics	N/A	-12.93%	-12.23%

Denali Therapeutics currently has a consensus target price of $34.25, indicating a potential upside of 58.13%. Janux Therapeutics has a consensus target price of $45.85, indicating a potential upside of 238.10%. Given Janux Therapeutics' higher probable upside, analysts clearly believe Janux Therapeutics is more favorable than Denali Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Denali Therapeutics	1 Sell rating(s)	1 Hold rating(s)	12 Buy rating(s)	1 Strong Buy rating(s)	2.87
Janux Therapeutics	2 Sell rating(s)	3 Hold rating(s)	9 Buy rating(s)	1 Strong Buy rating(s)	2.60

Janux Therapeutics has lower revenue, but higher earnings than Denali Therapeutics. Denali Therapeutics is trading at a lower price-to-earnings ratio than Janux Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Denali Therapeutics	$330.53M	10.40	-$512.54M	-$2.88	N/A
Janux Therapeutics	$10M	82.69	-$113.62M	-$1.84	N/A

Denali Therapeutics has a beta of 1.03, indicating that its share price is 3% more volatile than the broader market. Comparatively, Janux Therapeutics has a beta of 2.53, indicating that its share price is 153% more volatile than the broader market.

In the previous week, Janux Therapeutics had 2 more articles in the media than Denali Therapeutics. MarketBeat recorded 3 mentions for Janux Therapeutics and 1 mentions for Denali Therapeutics. Denali Therapeutics' average media sentiment score of 1.87 beat Janux Therapeutics' score of 1.25 indicating that Denali Therapeutics is being referred to more favorably in the media.

Company	Overall Sentiment
Denali Therapeutics	Very Positive
Janux Therapeutics	Positive

92.9% of Denali Therapeutics shares are owned by institutional investors. Comparatively, 75.4% of Janux Therapeutics shares are owned by institutional investors. 12.5% of Denali Therapeutics shares are owned by company insiders. Comparatively, 7.9% of Janux Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Summary

Janux Therapeutics beats Denali Therapeutics on 9 of the 15 factors compared between the two stocks.

How does Janux Therapeutics compare to Beam Therapeutics?

Beam Therapeutics (NASDAQ:BEAM) and Janux Therapeutics (NASDAQ:JANX) are both medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their institutional ownership, earnings, media sentiment, valuation, dividends, profitability, risk and analyst recommendations.

Beam Therapeutics has a beta of 2.25, suggesting that its stock price is 125% more volatile than the broader market. Comparatively, Janux Therapeutics has a beta of 2.53, suggesting that its stock price is 153% more volatile than the broader market.

In the previous week, Beam Therapeutics had 2 more articles in the media than Janux Therapeutics. MarketBeat recorded 5 mentions for Beam Therapeutics and 3 mentions for Janux Therapeutics. Beam Therapeutics' average media sentiment score of 1.30 beat Janux Therapeutics' score of 1.25 indicating that Beam Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Beam Therapeutics	3 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Janux Therapeutics	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

99.7% of Beam Therapeutics shares are owned by institutional investors. Comparatively, 75.4% of Janux Therapeutics shares are owned by institutional investors. 3.8% of Beam Therapeutics shares are owned by company insiders. Comparatively, 7.9% of Janux Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Beam Therapeutics has higher revenue and earnings than Janux Therapeutics. Beam Therapeutics is trading at a lower price-to-earnings ratio than Janux Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Beam Therapeutics	$139.74M	21.37	-$79.99M	-$0.68	N/A
Janux Therapeutics	$10M	82.69	-$113.62M	-$1.84	N/A

Janux Therapeutics has a net margin of 0.00% compared to Beam Therapeutics' net margin of -39.66%. Janux Therapeutics' return on equity of -12.93% beat Beam Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Beam Therapeutics	-39.66%	-29.00%	-22.61%
Janux Therapeutics	N/A	-12.93%	-12.23%

Beam Therapeutics presently has a consensus target price of $46.83, indicating a potential upside of 61.33%. Janux Therapeutics has a consensus target price of $45.85, indicating a potential upside of 238.10%. Given Janux Therapeutics' higher possible upside, analysts clearly believe Janux Therapeutics is more favorable than Beam Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Beam Therapeutics	1 Sell rating(s)	3 Hold rating(s)	9 Buy rating(s)	1 Strong Buy rating(s)	2.71
Janux Therapeutics	2 Sell rating(s)	3 Hold rating(s)	9 Buy rating(s)	1 Strong Buy rating(s)	2.60

Summary

Janux Therapeutics beats Beam Therapeutics on 8 of the 15 factors compared between the two stocks.

How does Janux Therapeutics compare to Tango Therapeutics?

Janux Therapeutics (NASDAQ:JANX) and Tango Therapeutics (NASDAQ:TNGX) are both medical companies, but which is the better investment? We will compare the two companies based on the strength of their earnings, valuation, dividends, risk, profitability, analyst recommendations, media sentiment and institutional ownership.

Janux Therapeutics has a beta of 2.53, meaning that its share price is 153% more volatile than the broader market. Comparatively, Tango Therapeutics has a beta of 1.19, meaning that its share price is 19% more volatile than the broader market.

Tango Therapeutics has higher revenue and earnings than Janux Therapeutics. Tango Therapeutics is trading at a lower price-to-earnings ratio than Janux Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Janux Therapeutics	$10M	82.69	-$113.62M	-$1.84	N/A
Tango Therapeutics	$62.38M	71.75	-$101.59M	-$0.83	N/A

Janux Therapeutics currently has a consensus price target of $45.85, indicating a potential upside of 238.10%. Tango Therapeutics has a consensus price target of $38.42, indicating a potential upside of 24.17%. Given Janux Therapeutics' higher possible upside, equities research analysts clearly believe Janux Therapeutics is more favorable than Tango Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Janux Therapeutics	2 Sell rating(s)	3 Hold rating(s)	9 Buy rating(s)	1 Strong Buy rating(s)	2.60
Tango Therapeutics	1 Sell rating(s)	2 Hold rating(s)	11 Buy rating(s)	0 Strong Buy rating(s)	2.71

75.4% of Janux Therapeutics shares are owned by institutional investors. Comparatively, 79.0% of Tango Therapeutics shares are owned by institutional investors. 7.9% of Janux Therapeutics shares are owned by insiders. Comparatively, 6.5% of Tango Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Janux Therapeutics has a net margin of 0.00% compared to Tango Therapeutics' net margin of -151.15%. Janux Therapeutics' return on equity of -12.93% beat Tango Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Janux Therapeutics	N/A	-12.93%	-12.23%
Tango Therapeutics	-151.15%	-41.54%	-33.44%

In the previous week, Tango Therapeutics had 20 more articles in the media than Janux Therapeutics. MarketBeat recorded 23 mentions for Tango Therapeutics and 3 mentions for Janux Therapeutics. Janux Therapeutics' average media sentiment score of 1.25 beat Tango Therapeutics' score of 0.10 indicating that Janux Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Janux Therapeutics	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Tango Therapeutics	3 Very Positive mention(s)	1 Positive mention(s)	5 Neutral mention(s)	2 Negative mention(s)	6 Very Negative mention(s)	Neutral

Summary

Janux Therapeutics beats Tango Therapeutics on 10 of the 17 factors compared between the two stocks.

How does Janux Therapeutics compare to Arcus Biosciences?

Arcus Biosciences (NYSE:RCUS) and Janux Therapeutics (NASDAQ:JANX) are both medical companies, but which is the better investment? We will contrast the two companies based on the strength of their analyst recommendations, risk, institutional ownership, profitability, earnings, dividends, media sentiment and valuation.

Arcus Biosciences currently has a consensus price target of $35.10, indicating a potential upside of 47.17%. Janux Therapeutics has a consensus price target of $45.85, indicating a potential upside of 238.10%. Given Janux Therapeutics' stronger consensus rating and higher probable upside, analysts clearly believe Janux Therapeutics is more favorable than Arcus Biosciences.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Arcus Biosciences	1 Sell rating(s)	3 Hold rating(s)	8 Buy rating(s)	0 Strong Buy rating(s)	2.58
Janux Therapeutics	2 Sell rating(s)	3 Hold rating(s)	9 Buy rating(s)	1 Strong Buy rating(s)	2.60

Janux Therapeutics has lower revenue, but higher earnings than Arcus Biosciences. Arcus Biosciences is trading at a lower price-to-earnings ratio than Janux Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Arcus Biosciences	$247M	12.14	-$353M	-$3.18	N/A
Janux Therapeutics	$10M	82.69	-$113.62M	-$1.84	N/A

Arcus Biosciences has a beta of 0.85, suggesting that its stock price is 15% less volatile than the broader market. Comparatively, Janux Therapeutics has a beta of 2.53, suggesting that its stock price is 153% more volatile than the broader market.

Janux Therapeutics has a net margin of 0.00% compared to Arcus Biosciences' net margin of -156.36%. Janux Therapeutics' return on equity of -12.93% beat Arcus Biosciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Arcus Biosciences	-156.36%	-68.97%	-35.27%
Janux Therapeutics	N/A	-12.93%	-12.23%

In the previous week, Arcus Biosciences had 5 more articles in the media than Janux Therapeutics. MarketBeat recorded 8 mentions for Arcus Biosciences and 3 mentions for Janux Therapeutics. Janux Therapeutics' average media sentiment score of 1.25 beat Arcus Biosciences' score of 0.75 indicating that Janux Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Arcus Biosciences	3 Very Positive mention(s)	1 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Janux Therapeutics	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

92.9% of Arcus Biosciences shares are owned by institutional investors. Comparatively, 75.4% of Janux Therapeutics shares are owned by institutional investors. 9.6% of Arcus Biosciences shares are owned by insiders. Comparatively, 7.9% of Janux Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Summary

Janux Therapeutics beats Arcus Biosciences on 13 of the 17 factors compared between the two stocks.

Get Janux Therapeutics News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding JANX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

JANX vs. The Competition

Export

Metric	Janux Therapeutics	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$826.89M	$3.39B	$6.53B	$12.05B
Dividend Yield	N/A	2.25%	2.67%	5.67%
P/E Ratio	-7.37	20.00	24.22	24.42
Price / Sales	82.69	305.69	511.60	109.90
Price / Cash	N/A	53.61	27.48	37.92
Price / Book	0.85	8.32	10.65	6.82
Net Income	-$113.62M	$23.94M	$3.57B	$337.56M
7 Day Performance	0.37%	1.84%	0.58%	1.17%
1 Month Performance	-2.38%	-0.04%	1.54%	3.16%
1 Year Performance	-45.54%	44.82%	25.40%	30.58%

Janux Therapeutics Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
JANX Janux Therapeutics	3.3449 of 5 stars	$13.56 flat	$45.85 +238.1%	-45.5%	$826.89M	$10M	N/A	30	Positive News
TLX Telix Pharmaceuticals	4.4896 of 5 stars	$9.22 -0.9%	$21.13 +129.1%	-40.6%	$3.16B	$803.79M	N/A	1,184
DNLI Denali Therapeutics	3.2157 of 5 stars	$19.54 +0.1%	$34.25 +75.3%	+48.9%	$3.10B	$330.53M	N/A	430	Positive News Gap Down
BEAM Beam Therapeutics	3.0781 of 5 stars	$29.78 +1.3%	$46.83 +57.3%	+70.2%	$3.02B	$139.74M	N/A	510	Positive News
TNGX Tango Therapeutics	2.354 of 5 stars	$30.93 +53.0%	$34.17 +10.5%	+559.7%	$2.92B	$62.38M	N/A	90	Gap Down High Trading Volume

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:JANX) was last updated on 6/15/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Janux Therapeutics (JANX) Competitors

JANX vs. TLX, DNLI, BEAM, TNGX, and RCUS

How does Janux Therapeutics compare to Telix Pharmaceuticals?

Summary

How does Janux Therapeutics compare to Denali Therapeutics?

Summary

How does Janux Therapeutics compare to Beam Therapeutics?

Summary

How does Janux Therapeutics compare to Tango Therapeutics?

Summary

How does Janux Therapeutics compare to Arcus Biosciences?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

JANX vs. The Competition

Janux Therapeutics Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Janux Therapeutics (JANX) Competitors

JANX vs. TLX, DNLI, BEAM, TNGX, and RCUS

How does Janux Therapeutics compare to Telix Pharmaceuticals?

Which has more volatility & risk, JANX or TLX?

Does the media favor JANX or TLX?

Do analysts prefer JANX or TLX?

Do insiders & institutionals believe in JANX or TLX?

Is JANX or TLX more profitable?

Which has stronger earnings & valuation, JANX or TLX?

Summary

How does Janux Therapeutics compare to Denali Therapeutics?

Is DNLI or JANX more profitable?

Do analysts prefer DNLI or JANX?

Which has better earnings & valuation, DNLI or JANX?

Which has more volatility & risk, DNLI or JANX?

Does the media prefer DNLI or JANX?

Do insiders & institutionals have more ownership in DNLI or JANX?

Summary

How does Janux Therapeutics compare to Beam Therapeutics?

Which has more volatility and risk, BEAM or JANX?

Does the media prefer BEAM or JANX?

Do institutionals and insiders have more ownership in BEAM or JANX?

Which has preferable valuation & earnings, BEAM or JANX?

Is BEAM or JANX more profitable?

Do analysts recommend BEAM or JANX?

Summary

How does Janux Therapeutics compare to Tango Therapeutics?

Which has more volatility and risk, JANX or TNGX?

Which has preferable earnings & valuation, JANX or TNGX?

Do analysts prefer JANX or TNGX?

Do institutionals and insiders have more ownership in JANX or TNGX?

Is JANX or TNGX more profitable?

Does the media favor JANX or TNGX?

Summary

How does Janux Therapeutics compare to Arcus Biosciences?

Do analysts recommend RCUS or JANX?

Which has preferable earnings & valuation, RCUS or JANX?

Which has more risk & volatility, RCUS or JANX?

Is RCUS or JANX more profitable?

Does the media refer more to RCUS or JANX?

Do institutionals and insiders believe in RCUS or JANX?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

JANX vs. The Competition

Janux Therapeutics Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools